How to Choose a Contract Research Organization in Canada: What Health Canada Submissions Really Demand

Every year, pharmaceutical companies entering Canada from the US or Europe make the same costly mistake: they select a contract research organization based on turnaround time and quoted price, then discover mid-submission that their CRO’s practices don’t align with what Health Canada expects.

The consequence isn’t just a delayed application. Under Canada’s Food and Drug Regulations, the Marketing Authorization Holder (MAH) bears full regulatory accountability for outsourced work. Section C.02.014 is explicit: written agreements must govern the relationship, quality oversight cannot be delegated away, and if your CRO’s data doesn’t hold up under Health Products and Food Branch (HPFB) scrutiny, the submission fails — and the remediation cost falls on you, not your vendor.

So let’s get specific about what selecting a contract research organization in Canada actually involves.

Why the MAH Stays on the Hook

Before evaluating any CRO, it’s worth understanding the regulatory architecture. Canada’s GMP framework — articulated in Division 2, Part C of the Food and Drug Regulations, and supported by Health Canada’s GUI-0001 Good Manufacturing Practices Guidelines — operates on a clear principle: outsourcing an activity does not outsource the obligation.

ICH Q10, which Health Canada formally adopted as part of its pharmaceutical quality system expectations, dedicates Annex 1 entirely to outsourced activities and purchased materials. The guidance requires that the contract giver establish and review quality agreements before work begins, maintain active oversight of the contract acceptor’s processes, and verify that the CRO’s quality system is compatible with its own.

That last point matters more than most companies realize. If your CRO classifies deviations differently than your internal SOPs define them, you’ll have gaps when an inspector starts asking how out-of-specification (OOS) results were handled. Health Canada’s HPFB inspectors are trained on ICH Q10 and they know what a mature quality system looks like. They will ask.

Check the DEL — and Check What It Actually Covers

Any Canadian CRO that manufactures, packages, labels, or tests drugs for commercial distribution must hold a valid Drug Establishment Licence (DEL), issued under Section 37 of the Food and Drugs Act. Health Canada maintains a public database of DEL holders, and that database should be your first stop — not a CRO’s sales presentation.

But confirming a DEL exists isn’t enough. The licence specifies:

• The activities the site is licensed to perform (fabrication, packaging and labelling, testing, importation, distribution, wholesaling)
• The dosage form categories covered (sterile injectables, oral solid dosage forms, biologics, and so on)
• Whether the site is licensed for Schedule F prescription drugs, controlled substances, or both

A CRO might hold a DEL for oral solid dosage forms but not for sterile products. If you’re developing an injectable, you need a site licensed for that specific category. We’ve seen companies three months into a contract testing agreement before discovering the CRO’s DEL didn’t cover their dosage form — requiring a DEL amendment that added significant time to an already tight development schedule.

DEL renewals also lapse. Confirm the licence expiry date and build a verification step into your quality agreement’s annual review cycle.

Five Criteria That Separate a Compliant Canadian CRO from a Costly One

Narrowing your selection to genuinely Health Canada-aligned partners requires going deeper than DEL status. Here’s where rigorous due diligence actually lives:

1. GMP Inspection History

Health Canada’s HPFB Inspectorate conducts routine GMP inspections of domestic sites on a risk-based schedule, typically ranging from 2 to 4 years depending on site classification and product risk. Ask prospective CROs for their most recent Establishment Inspection Report (EIR). A CRO unwilling to share inspection outcomes — even with a confidentiality agreement in place — should raise immediate questions.

When you do review an EIR, look beyond whether Observations exist. Look for patterns. A site with repeat Observations in data integrity or equipment qualification across two consecutive inspections hasn’t fixed the root cause.

2. Quality Agreement Depth

The quality agreement is not a formality. Under Health Canada’s expectations aligned with ICH Q10, it must define clear responsibilities for change control, deviation handling, OOS investigations, batch record review, sample retention, and regulatory notification timelines — at minimum. A three-page template agreement signals a CRO that treats compliance as a checkbox rather than an operating philosophy.

Ask to review a redacted version of an agreement they’ve executed with a comparable client. It tells you more than any reference call.

3. Method Validation to Applicable Standards

Canadian drug submissions reference USP, Ph.Eur., or Health Canada’s own guidance documents depending on the product type. Your CRO’s analytical methods must be validated in accordance with ICH Q2(R1), and that validation documentation must be submission-ready — formatted and packaged for direct inclusion in Module 3 of a CTD.

Ask specifically: “Can you provide method validation reports formatted for an ANDS or NDS submission?” If the answer involves substantial reformatting on your end, build that time and cost into your project plan.

4. Regulatory Track Record for Your Specific Pathway

An Abbreviated New Drug Submission (ANDS) for a generic oral solid has very different data requirements than a New Drug Submission (NDS) for an innovative product or a Clinical Trial Application (CTA) for a Phase II study. Some CROs specialize in bioequivalence data packages; others are stronger in stability programs or CMC documentation.

Map the CRO’s specific track record to your submission type. Ask for examples — anonymized if necessary — of accepted submissions they contributed data to. Health Canada’s standard review target for a priority NDS is 180 days; for a standard NDS, it’s 300 days. A CRO that has contributed to multiple successful submissions within those timelines understands what the agency expects in the data package.

5. Quality System Compatibility

This is the criterion most companies assess last, if at all. Your internal SOPs for change control, labelling reconciliation, and batch disposition must integrate cleanly with the CRO’s processes. If there’s a structural mismatch, you’ll spend months negotiating procedural interfaces that should have been resolved before the contract was signed.

We recommend running a short tabletop exercise during vendor qualification: walk through a hypothetical OOS result together and trace how it moves through both quality systems. Mismatches surface quickly and clearly.

Questions That Cut Through the Marketing Language

Beyond formal criteria, direct questions during vendor qualification reveal a lot. A competent CRO team answers these without needing to escalate to management:

• “What’s your current sample backlog, and what’s your realistic turnaround for 12-month ICH stability timepoints?” A CRO that can’t answer with a specific number is over capacity.
• “Which Health Canada guidance documents do your analytical staff reference for impurity profiling?” They should immediately cite ICH Q3A, Q3B, and ICH M7 — without hesitation.
• “How do you handle a change control request from a client that affects a validated method?” Look for a documented change management process with defined timelines, not a vague assurance.
• “What’s your SOP for notifying clients of critical deviations during a study?” Industry best practice is a 24-hour notification window for critical events. If they don’t have a defined timeline, that’s a gap.

Red Flags Worth Walking Away From

A few patterns appear consistently in problematic outsourcing relationships:

Vague scope in the service agreement. If the contract doesn’t define which party owns which regulatory deliverable, disputes emerge exactly when you can’t afford them — during a Health Canada inspection or a submission deficiency response.

No in-house regulatory affairs staff. Some CROs provide testing services with no regulatory expertise on staff. That’s acceptable for standalone analytical work, but if you’re expecting the CRO to contribute to your submission narrative, their regulatory staff must be involved from study design — not retroactively, after data generation is complete.

Overpromised timelines. Health Canada’s review timelines are fixed by the priority classification of your submission. What varies is the quality of the data package you submit. A CRO that guarantees a fast development timeline without first reviewing your data requirements is telling you what you want to hear.

Single-laboratory dependency. If a CRO routes all analytical work through one testing facility, and that facility fails an accreditation audit or experiences a major equipment failure, your stability program stalls. Ask about backup analytical capabilities and sub-contractor qualification procedures before you’re in a situation where it matters.

A thorough vendor qualification — including document review, a site visit, and reference conversations — typically runs 6 to 10 weeks when done properly. That timeline surprises companies who expected to be operational with a CRO partner within a month of starting the search. Build it into your development schedule before you’re already behind.

The regulatory accountability stays with the MAH. The partner you choose determines whether managing that accountability is a routine part of your quality program or a problem you’re solving the night before a submission deadline.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance Contact us

Related from our network

• ISO 17025-accredited pharmaceutical and supplement testing in the US — Qalitex Laboratories provides contract analytical testing for cross-border drug submissions and US market compliance.
• Regulatory consulting and cosmetics compliance for the European market — Care Europe supports pharmaceutical and consumer product companies entering the EU under relevant directives and regulations.